Small molecule inhibitors of PDGFR/KIT-family RTKs (e.g. imatinib) are routinely being used for the treatment of gastrointestinal stromal tumors (GIST) and some leukemias, but not CRC (10). This evidence concerns the gene KIT and colorectal carcinoma.